share_log

6-K: New data for arexvy, gsk's respiratory syncytial virus vaccine, show potential to help protect a broader group of adults at increased risk for rsv disease

6-K: New data for arexvy, gsk's respiratory syncytial virus vaccine, show potential to help protect a broader group of adults at increased risk for rsv disease

6-K:GSK呼吸道合胞病毒疫苗Arexvy的新數據顯示可能有助於保護更廣泛的成年人群體RSV疾病的風險
美股SEC公告 ·  10/24 18:53
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息